Characterizing the Molecular Mechanisms of PRSS56-Dependent Ocular Growth and Refractive Error
表征 PRSS56 依赖性眼生长和屈光不正的分子机制
基本信息
- 批准号:10705558
- 负责人:
- 金额:$ 39.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAffectAgonistAnimal ModelAttentionBiochemicalBlindnessCallithrixCell Culture TechniquesCell physiologyClinicalCuesDefectDeletion MutationDependovirusDevelopmentDiseaseExtracellular MatrixEyeGene TargetingGeneticGenetic ProcessesGenetic studyGlaucomaGoalsGrowthHumanHyperopiaImageIndividualInterventionIntrinsic driveInvestigationLengthLinkMacular degenerationMediatingMediatorMessenger RNAMicrophthalmosModernizationMolecularMuller&aposs cellMusMutant Strains MiceMutationMyopiaOpticsPathogenesisPathway interactionsPrevalenceProcessProteomicsPublic HealthRefractive ErrorsRegulationRetinaRetinal DetachmentRiskRoleScleraSeriesSerine ProteaseSerine Proteinase InhibitorsSignal TransductionStructure of retinal pigment epitheliumTestingTimeTransgenic OrganismsTranslatingVariantVisionVisualWNT Signaling Pathwaybeta catenincell typeconditional mutantdeprivationemmetropizationexperimental studyfallsgenetic approachinsightlenslens inductionmouse modelnew therapeutic targetoverexpressionpostnatalpostnatal developmentprenatalpreventprogramsresponsetargeted treatmenttherapeutic targettrypsin-like serine protease
项目摘要
Abstract
Refractive errors are a major cause of vision loss worldwide, and the rising prevalence of myopia and
associated blinding conditions is a significant public health concern. Regulation of ocular axial growth is critical
for normal refractive development to ensure that a focused image falls directly on the retina. Our goal is to
decode the molecular and genetic program that governs ocular axial growth. Ocular growth is driven by an
intrinsic, genetic process during prenatal and postnatal development (vision-unadjusted) and by a postnatal,
vision-guided process, emmetropization, thought to interact with intrinsic ocular growth such that the eye's
axial length matches its optical power. Enhanced intrinsic ocular growth and defective emmetropization are
thought to cause a mismatch between ocular axial length and optical power, leading to myopia. Ocular axial
growth relies on signals from the retina to the sclera to promote extracellular matrix remodeling and ocular
elongation. However, the mechanisms by which the signals translate to ocular axial growth remain elusive. Our
studies suggest that PRSS56, a secreted serine protease, is a component of the intrinsic machinery that
supports ocular axial growth. However, it is not known whether Prss56 has a direct role in emmetropization.
We propose to uncover the molecular and cellular processes underlying PRSS56-dependent refractive
development and associated errors and assess the role of PRSS56 in vision-guided ocular growth.
Despite evidence that altered expression of PRSS56 affects ocular axial length, the factors that regulate its
expression and mediate its effect are not known. The Wnt-mediated pathway is associated with myopia
pathogenesis, and we have found that Prss56 responds to Wnt signaling agonists. In Aim 1, we will elucidate
the link between Wnt and Prss56 by modulating WNT activity in genetic mouse models and studying the effect
on the retinal expression of PRSS56 and ocular growth (Aim 1.1). We will also determine, in conditional mouse
models, whether retinal pigment epithelium–localized Serpine3—which we identified as a candidate mediator
of PRSS56-dependent growth—helps relay PRSS56-dependent signals that support ocular growth (Aim 1.2).
In Aim 2, we will characterize the function of PRSS56 to guide the identification of its substrate(s) and targeted
therapies. In Aim 3, we will test the role of PRSS56 in emmetropization and PRSS56-dependent regulation of
ocular axial growth by temporarily inactivating PRSS56 in conditional mutant mice and using experimental
paradigms that induce axial elongation in response to visual blur or optical defocus.
The proposed studies will provide a molecular and genetic framework to understand the mechanisms of ocular
growth and guide us to potential therapeutic targets to manage myopia.
抽象的
屈光不正是全世界视力丧失的主要原因,近视和近视患病率不断上升
相关的致盲病症是一个重要的公共卫生问题,调节眼轴生长至关重要。
正常屈光发育,确保聚焦图像直接落在视网膜上。
解码控制眼轴生长的分子和遗传程序。
产前和产后发育(视力未调整)和产后的内在遗传过程,
视觉引导过程,正视化,被认为与内在的眼睛生长相互作用,使得眼睛的
眼轴长度与其屈光力相匹配,眼睛的内在生长增强,正视度有缺陷。
被认为会导致眼轴长度与屈光力不匹配,从而导致眼轴。
信号的生长依赖于视网膜到巩膜来促进细胞外基质重塑和眼部
然而,信号转化为眼轴生长的机制仍然难以捉摸。
研究表明,PRSS56(一种分泌型丝氨酸蛋白酶)是内在机制的一个组成部分,
支持眼轴生长。然而,尚不清楚 Prss56 是否对正视眼有直接作用。
我们建议揭示 PRSS56 依赖性屈光背后的分子和细胞过程
发育和相关错误,并评估 PRSS56 在视觉引导眼部生长中的作用。
尽管有证据表明 PRSS56 表达的改变会影响眼轴长度,但调节其的因素
Wnt 介导的通路与近视有关。
发病机制,我们发现 Prss56 对 Wnt 信号激动剂有反应。在目标 1 中,我们将阐明。
通过在遗传小鼠模型中调节 WNT 活性并研究其效果,揭示 Wnt 和 Prss56 之间的联系
我们还将在有条件的小鼠中确定 PRSS56 的视网膜表达和眼睛生长的关系(目标 1.1)。
模型,无论是视网膜色素上皮 - 定位的 Serpine3 - 我们确定为候选介质
PRSS56 依赖性生长——帮助传递支持眼睛生长的 PRSS56 依赖性信号(目标 1.2)。
在目标 2 中,我们将描述 PRSS56 的功能,以指导其底物和目标的识别。
在目标 3 中,我们将测试 PRSS56 在正视化和 PRSS56 依赖性调节中的作用。
通过暂时灭活条件突变小鼠中的 PRSS56 并使用实验
响应视觉模糊或光学散焦而引起轴向伸长的范例。
拟议的研究将为理解眼部疾病的机制提供分子和遗传框架。
增长并指导我们找到控制近视的潜在治疗目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kayarat Saidas Nair其他文献
Kayarat Saidas Nair的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kayarat Saidas Nair', 18)}}的其他基金
Determining Molecular Mechanisms of Human Glaucoma Genes
确定人类青光眼基因的分子机制
- 批准号:
10444972 - 财政年份:2022
- 资助金额:
$ 39.94万 - 项目类别:
Determining Molecular Mechanisms of Human Glaucoma Genes
确定人类青光眼基因的分子机制
- 批准号:
10612930 - 财政年份:2022
- 资助金额:
$ 39.94万 - 项目类别:
Characterizing the Molecular Mechanisms of PRSS56-Dependent Ocular Growth and Refractive Error
表征 PRSS56 依赖性眼生长和屈光不正的分子机制
- 批准号:
10367868 - 财政年份:2022
- 资助金额:
$ 39.94万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
9211347 - 财政年份:2014
- 资助金额:
$ 39.94万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
8788029 - 财政年份:2014
- 资助金额:
$ 39.94万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
8784082 - 财政年份:2014
- 资助金额:
$ 39.94万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
9003054 - 财政年份:2014
- 资助金额:
$ 39.94万 - 项目类别:
Determining Molecular and Cellular Mechanisms of Glaucoma
确定青光眼的分子和细胞机制
- 批准号:
8418312 - 财政年份:2013
- 资助金额:
$ 39.94万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
cAMP信号激动剂对恶性胶质瘤血管新生和血管正常化的影响及机制研究
- 批准号:81803568
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Liberating methadone: Building a roadmap and community for change
解放美沙酮:建立变革路线图和社区
- 批准号:
10683560 - 财政年份:2023
- 资助金额:
$ 39.94万 - 项目类别:
Optogenetic and chemogenetic regulation of uterine vascular function
子宫血管功能的光遗传学和化学遗传学调控
- 批准号:
10785667 - 财政年份:2023
- 资助金额:
$ 39.94万 - 项目类别:
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
$ 39.94万 - 项目类别:
A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection
预防淋病奈瑟菌感染的新型舌下疫苗
- 批准号:
10699065 - 财政年份:2023
- 资助金额:
$ 39.94万 - 项目类别:
Probing Mechanisms of Polycystin-1 Regulation Using Peptide Modulators Designed by Sequence- and Structure-Based Learning
使用基于序列和结构的学习设计的肽调制器探索多囊蛋白-1 调节机制
- 批准号:
10917464 - 财政年份:2023
- 资助金额:
$ 39.94万 - 项目类别: